Art Krieg, Checkmate Pharmaceuticals
Regeneron buys Art Krieg’s biotech startup for a discount price, boosting I/O pipeline
Jumping into the M&A game, Regeneron has scooped up a beaten down Checkmate Pharmaceuticals for $250 million in cash, bagging its lead drug for melanoma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
